使用干扰素完全治愈HBV相关性肝细胞癌伴肺转移的患者，生

StephenW

Oncol Lett. 2018 Sep;16(3):2979-2988. doi: 10.3892/ol.2018.9033. Epub 2018 Jun 28.
Complete cure of a patient with HBV-associated hepatocellular carcinoma with lung metastasis using interferon and survival up to 108 months: A case report and literature review.
Wang F1,2,3,4, Lv H1,2,3,4, Li Y1,2,3,4, Han T1,2,3,4, Liu H1,2,3,4, Jia K2,3,4, Liu F1,2,3,4, Gao Y1,2,3,4, Wang F1,2,3,4.
Author information

1
    Department of Gastroenterology and Hepatology, The Third Central Hospital of Tianjin, Hedong, Tianjin 300170, P.R. China.
2
    Tianjin Institute of Hepatobiliary Disease, Hedong, Tianjin 300170, P.R. China.
3
    Tianjin Key Laboratory of Artificial Cells, Hedong, Tianjin 300170, P.R. China.
4
    Artificial Cell Engineering Technology Research Center of The Public Health Ministry, Hedong, Tianjin 300170, P.R. China.

Abstract

Hepatocellular carcinoma (HCC) has a poor prognosis due to its asymptomatic onset and susceptibility to metastasis. The survival of patients with advanced HCC is 6-12 months. As a first-line medicine for the control of hepatitis B virus, interferon (IFN) is also capable of inhibiting tumor growth and modulating immunity. However, treatment of HCC with lung metastasis using IFN has been rarely reported. The present study reports the case of one patient with HCC having lung metastasis who underwent a one-time treatment with transcatheter arterial chemoembolization (TACE) and was subsequently completely cured by single peginterferon α 2a (PEG-IFNα2a); and has survived up to 108 months. A 53-year-old male patient diagnosed with HBV-related HCC with lung metastasis underwent TACE using floxuridine (FUDR) 500 mg, cisdiamine dichloroplatinum (CDDP) 20 mg, mitomycin 10 mg, and ultrafluid lipiodol 10 ml, together with local thoracic aorta chemotherapy using FUDR 250 mg and CDDP 20 mg. His metastatic lung cancer aggravated. However, after 9 months of treatment with subcutaneous injections of PEG-IFNα 2a once per week, the metastatic lung foci gradually shrunk until disappearance and the HCC lesion stabilized without progression. According to the World Health Organization criteria for the efficacy of solid tumors, this was a case of complete response. Upon follow-up up to 108 months his metastatic lung cancer had disappeared and HCC did not recur. Therefore, IFN intervention may be an appropriate novel adjuvant therapy for patients with HCC with lung metastasis and requires further attention and study.
KEYWORDS:

hepatitis B virus; hepatocellular carcinoma; interferon; lung metastasis

PMID:
    30127887
PMCID:
    PMC6096095
DOI:
    10.3892/ol.2018.9033

StephenW

Oncol Lett。 2018年9月; 16（3）：2979-2988。 doi：10.3892 / ol.2018.9033。 Epub 2018年6月28日。
使用干扰素完全治愈HBV相关性肝细胞癌伴肺转移的患者，生存期长达108个月：病例报告和文献综述。
Wang F1,2,3,4，Lv H1,2,3,4，Li Y1,2,3,4，Han T1,2,3,4，Liu H1,2,3,4，Jia K2,3， 4，刘F1,2,3,4，高Y 1,2,3,4，王F1,2,3,4。
作者信息

1
    天津市第三中心医院消化内科，天津河东，天津300170，中国。
2
    天津市河东省肝胆病研究所，天津300170，中国。
3
    天津市天津市人工细胞重点实验室，天津300170，中国。
4
    天津市河东省公共卫生部人工细胞工程技术研究中心，天津300170，中国。

抽象

肝细胞癌（HCC）由于其无症状发作和易于转移而预后不良。晚期HCC患者的生存期为6-12个月。作为控制乙型肝炎病毒的一线药物，干扰素（IFN）也能够抑制肿瘤生长和调节免疫。然而，很少报道使用IFN治疗具有肺转移的HCC。本研究报告了一例HCC患有肺转移的患者，该患者接受了经导管动脉化疗栓塞（TACE）一次性治疗，随后通过单一聚乙二醇干扰素α2a（PEG-IFNα2a）完全治愈;并存活了108个月。诊断患有肺转移HBV相关HCC A 53岁的男性患者，本地胸主动脉进行TACE使用氟尿苷（FUDR）500毫克，cisdiamine二氯铂（CDDP）20毫克，丝裂霉素10毫克，和ultrafluid碘油10毫升，一起化疗使用FUDR 250 mg和CDDP 20 mg。他的转移性肺癌恶化。然而，在每周皮下注射PEG-IFNα2a治疗9个月后，转移性肺病灶逐渐收缩直至消失，并且HCC病变稳定而没有进展。根据世界卫生组织关于实体瘤疗效的标准，这是一个完全反应的案例。随访长达108个月，他的转移性肺癌已经消失，HCC没有复发。因此，IFN干预可能是HCC肺转移患者的一种合适的新型辅助治疗方法，需要进一步关注和研究。
关键词：

乙型肝炎病毒;肝细胞癌;干扰素;肺转移

结论：
    30127887
PMCID：
    PMC6096095
DOI：
    10.3892 / ol.2018.9033

StephenW

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096095/